WSJ Tech News Briefing — Using AI to See the Hidden Signs of Breast Cancer

Date: October 3, 2025
Host: Peter Ciampelli
Guests: Nicole Nguyen (WSJ Personal Tech Columnist), Brianna Abbott (WSJ Reporter), Katie Dayton (WSJ Contributor)

Episode Overview

This episode explores two rapidly evolving realms of AI technology: smarter automation in the home and groundbreaking advances in medical imaging for cancer risk prediction. The first half focuses on major upgrades headed to consumer smart home devices like security cameras and assistants. The second half dives into new AI tools that can predict the risk of breast cancer from a single mammogram, potentially transforming clinical screening and diagnostics.

Smarter, AI-Driven Smart Home Tech

Guest: Nicole Nguyen, WSJ Personal Tech Columnist

Key Discussion Points

• Major AI Upgrades for Cameras

  • Security cameras (Nest, Ring) are about to get much smarter, thanks to AI integration.
  • New abilities include understanding scene context, so notifications are more useful and less generic.
  • Example: Google’s Gemini allows specific queries like, “What’s eating my plants?” The AI reviews footage and can identify, for instance, rabbits in the garden.
  • Amazon leverages its whole network of Ring cameras for tasks like locating missing pets, using AI to identify animals across multiple devices.

• Networked AI for Community Problem-Solving

  • Ring owner can initiate a search for a lost dog, with local cameras looking for the pet and owners able to opt-in to share relevant footage.
  • This technology has potential broader applications, e.g., for finding missing persons who have dementia.

• Quote Highlight

  • “In this demo that I saw, [Gemini] surfaced a video clip of two rabbits munching on grass.” — Nicole Nguyen [02:09]
  • “You can trigger a search party in the app [Ring] which will look for your pup using AI in footage captured by nearby cameras.” — Nicole Nguyen [02:37]

• Privacy and Security Concerns

  • Previous controversy involving Ring’s sharing of footage with law enforcement has made opt-in sharing crucial for these new features.

  • Owners remain in full control over whether to share footage triggered by AI events.

    • “The head of Ring told us it was really important for Ring camera owners [...] to be able to opt in or out of sharing.” — Nicole Nguyen [03:29]

• Smart Home 2.0: Natural Language Automations

  • Early smart home tech was largely timer-based or required complex, multi-app routines.

  • The new wave allows users to trigger complex automations with simple statements, e.g. “Make me feel safer,” prompting actions like checking doors, windows, and toggling lights automatically.

    • “A lot of those automations and routines will be triggered by natural language.” — Nicole Nguyen [04:20]

Timestamps:

• [01:24] — AI changes coming to smart security cameras
• [03:16] — Privacy and opt-in controls discussion
• [03:56] — Comparing “Smart Home 1.0” vs. “2.0”
• [04:54] — Segment transition

Fighting Breast Cancer with AI: A Clinical Frontier

Guests:

• Brianna Abbott, Wall Street Journal Reporter
• Interviewed by Katie Dayton

Key Discussion Points

• Traditional Breast Cancer Risk Assessments

  • Typically use quiz-based calculators including factors like age, ethnicity, breast density, and menopausal status.

  • Classifies a 3% five-year risk as high, or a 20%+ lifetime risk as high.

    • “They quiz women on their age, their ethnicity, breast density, menopausal status, like things that are well known to raise or lower your breast cancer risk.” — Brianna Abbott [06:10]

• Limitations of Current Tools

  • Existing calculators are only accurate about 60% of the time.

  • AI models already surpass that, achieving 70-80% accuracy in discriminating future cancer cases, representing a meaningful jump in predictive ability (but are not perfect).

    • “For the AI models [...] that increases to 70% of the time or more.” — Brianna Abbott [06:54]
    • “That is a pretty big jump. But it’s still obviously not perfect.” — Brianna Abbott [07:14]

• AI’s Unique Capabilities

  • Human radiologists cannot reliably use a single mammogram to identify future cancer risk.

  • AI can analyze vast sets of scans linked to later outcomes, offering a personalized risk score from one image.

    • “She can’t look at a mammogram and predict a woman’s five year risk of breast cancer with any accuracy. But that is the point where the AI is able to step in.” — Brianna Abbott [07:40]

• Potential Downsides and Challenges

  • Over-flagging of lower-risk women, leading to unnecessary tests or even preventative treatments.

  • Questions remain about bias: AIs trained on one population might not generalize well; e.g., white vs. Black patient populations.

  • Regulatory gap: FDA does not require clinical trials for these AI tools, so some in medicine want more rigorous evidence.

    • “There’s a risk that you flag a lot of women who are lower risk [...] when they didn’t necessarily have to do that.” — Brianna Abbott [08:24]
    • “If you train it on a data set of predominantly white patients, how well is it going to work in a hospital that has predominantly black patients?” — Brianna Abbott [08:44]

• Regulatory and Clinical Reality

  • No clinical trials required for approval (unlike medicines), but they're desired by many radiologists to prove real impacts like reduced mortality or late-stage disease.

  • Fast pace of AI makes traditional clinical trial timelines challenging — by the end of a five-year trial, the model tested may be outdated.

    • “The way that the Food and Drug Administration works is that these AI models don’t actually need to go through clinical trials to get approved.” — Brianna Abbott [09:21]
    • “The bar that these models need to clear is not as high as a pharmaceutical drug.” — Brianna Abbott [09:31]

• Deployment Timeline

  • Clarity AI received FDA approval earlier in 2025; roll-out in clinics is expected by end of year, others (Deep Health) close behind.

  • Applications to other cancers and genetic conditions are in earlier stages.

    • “You could be seeing something like this at your routine mammogram somewhere sooner than you think.” — Brianna Abbott [10:39]

Timestamps:

• [06:08] — Overview of current breast cancer risk calculators
• [06:45] — Comparing AI accuracy to existing methods
• [07:36] — AI’s ability to predict from a single scan
• [08:20] — Concerns about false positives and population bias
• [09:21] — Regulatory discussion: FDA, clinical trials
• [10:30] — First approvals and what’s next

Notable Quotes

• “In this new wave of smart home stuff, which we can call Smart Home 2.0, a lot of those automations and routines will be triggered by natural language.”
  — Nicole Nguyen [04:20]

• “The algorithm can basically come up with a way to spit out a risk score from a single scan.”
  — Brianna Abbott [07:55]

• “Some of the AI companies, their response to that is why would we be held to a higher standard that these quiz calculators are not?”
  — Brianna Abbott [10:06]

Summary

This episode captures two pivotal trends at the intersection of AI and everyday life: smarter, context-aware smart homes and a paradigm shift in disease risk assessment via AI-analyzed imaging. The discussion underscores both the promise—more meaningful alerts and detection, earlier interventions for disease—and the pitfalls, such as privacy, regulatory, and algorithmic fairness concerns. Real-world deployment of AI tools for breast cancer risk in the clinic is imminent, heralding a future where simple scans could reveal hidden medical threats years in advance.